Welcome to our dedicated page for Neurosense Therapeutics news (Ticker: NRSN), a resource for investors and traders seeking the latest updates and insights on Neurosense Therapeutics stock.
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) is a clinical-stage biotechnology company developing novel treatments for severe neurodegenerative diseases, with a primary focus on amyotrophic lateral sclerosis (ALS) and Alzheimer's disease. Its news flow centers on the clinical and regulatory progress of its lead drug candidate, PrimeC, a novel extended-release oral formulation combining two FDA-approved drugs, ciprofloxacin and celecoxib, in a fixed dose designed to target multiple disease mechanisms.
News updates for NRSN commonly cover milestones in ALS and Alzheimer’s clinical programs. These include Phase 2 and Phase 2b trial readouts, such as the PARADIGM study in ALS and the RoAD proof-of-concept study in Alzheimer’s disease, along with biomarker analyses that the company uses to interpret treatment effects. Press releases also highlight safety and tolerability findings, including reports of favorable safety profiles and absence of new or unexpected safety signals in clinical studies.
Investors and observers can expect coverage of regulatory interactions, such as FDA clearance to initiate a pivotal Phase 3 trial of PrimeC in ALS, database lock announcements for Alzheimer’s trials, and updates on planned submissions to agencies like Health Canada. Corporate and financing developments, including private placements of ordinary shares and business updates, are also frequent topics.
This news page aggregates these company-issued announcements, SEC-related communications and other public disclosures about NeuroSense’s progress. It is useful for readers who want to follow NRSN’s clinical trial milestones, biomarker-driven research updates, regulatory steps and capital-raising activities as the company advances PrimeC in ALS and Alzheimer’s disease.
NeuroSense Therapeutics (Nasdaq: NRSN) announced its annual report for 2022, showcasing significant developments in its clinical trials and financials. The company is advancing its lead candidate PrimeC for ALS, with over 50% patient enrollment in the Phase 2b PARADIGM trial, expected to report topline results in H2 2023. Positive preliminary findings from a biomarker study in Alzheimer's disease prompted plans for a Phase 2 trial in H1 2023. However, R&D expenses surged by 108% to $6.4 million, and general administrative costs increased by 185% to $7.1 million, reflecting expanding operational activities. Cash reserves stood at $7.1 million.
NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) announced participation in the 17th annual BIO-Europe Spring conference on March 20-22, 2023 in Basel, Switzerland. Chief Medical Officer Dr. Ferenc Tracik and VP of Business Development Nedira Salzman-Frenkel will meet potential partners regarding the company's drug development pipeline. NeuroSense's lead drug, PrimeC, is in a global Phase 2b study for ALS, with results expected in H2 2023. Other programs include Alzheimer's and Parkinson's disease treatments, with key milestones expected in 2023.
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) will participate in Renmark Financial Communications' Virtual Non-Deal Roadshow Series on March 21, 2023, at 11:00 AM PST, and March 28, 2023, at 10:00 AM EST. The sessions will feature CEO Alon Ben-Noon and VP Nedira Salzman-Frenkel, focusing on the latest investor presentation and a live Q&A. Interested investors can register for the events, with limited spots available. Replays will be accessible later on the company's investor website. NeuroSense is dedicated to developing treatments for neurodegenerative diseases, addressing significant unmet medical needs in this area.
NeuroSense Therapeutics (NASDAQ: NRSN) recently shared a corporate update highlighting growth opportunities for 2023. The company anticipates topline results from its Phase 2b clinical trial in amyotrophic lateral sclerosis (ALS) in H2 2023, with enrollment already over 50% complete across four countries. Additionally, promising Alzheimer's disease biomarker results were announced, leading to a planned Phase 2 study in the first half of 2023. A Parkinson's disease biomarker study is also ongoing, with results expected soon. CEO Alon Ben-Noon expressed optimism about the company’s performance in 2022 and future milestones.
NeuroSense Therapeutics (NASDAQ: NRSN) has announced a collaboration with QuantalX Neuroscience to utilize Delphi-MD, a neurodiagnostic technology, in their upcoming Phase 2 clinical trial for Alzheimer's disease (AD). This trial is expected to commence in H1 2023 and aims to enhance early diagnosis and treatment of neurodegenerative diseases. Delphi-MD will provide objective measurements of brain function, supporting improved patient care. The partnership also anticipates using this technology in a future Phase 3 trial for PrimeC, NeuroSense's lead drug candidate for ALS treatment, pending successful Phase 2b trial results.
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) announced regulatory approval from Germany's BfArM for its Clinical Trial Application to enroll patients in the PARADIGM study, a Phase 2b trial for PrimeC in treating amyotrophic lateral sclerosis (ALS). The study is set to include participants from Israel, Italy, Canada, and Germany, with over 50% of the 69 planned patients already enrolled. Topline results are anticipated in the second half of 2023. PrimeC combines two FDA-approved drugs aimed at addressing several mechanisms involved in ALS progression. The drug has previously met safety and efficacy endpoints in Phase 2a trials.
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) has received regulatory approval from Health Canada to initiate patient enrollment in its Phase 2b PARADIGM study for the treatment of amyotrophic lateral sclerosis (ALS) using its novel combination therapy, PrimeC. Over 50% of patients are already enrolled, with topline results expected in the second half of 2023. Following FDA's request for additional non-clinical data, NeuroSense has withdrawn its study protocol from the U.S. Investigational New Drug application and plans to align its strategy for a potential pivotal Phase 3 trial. PrimeC, a fixed-dose combination of ciprofloxacin and celecoxib, aims to target ALS progression effectively.
NeuroSense Therapeutics (NASDAQ: NRSN) has reported positive results from a biomarker study evaluating its combination therapy for Alzheimer's disease (AD). The study found elevated levels of TDP-43, a novel biomarker, in AD patients compared to healthy controls. NeuroSense plans to expand the study to further validate these findings and anticipates starting a Phase 2 double-blind proof-of-concept clinical trial in the first half of 2023. TDP-43's relevance in AD is highlighted by its association with cognitive impairment severity, presenting potential for NeuroSense's therapy in addressing significant unmet medical needs in neurodegenerative diseases.
NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) reported its Q3 2022 financial results, highlighting notable milestones in its Phase 2b ALS study. The FDA accepted NeuroSense's IND, allowing for patient enrollment in the U.S. and Italy. As of September 30, 2022, the company had $8.4 million in cash and short-term deposits, sufficient to fund operations into Q4 2023. R&D expenses rose to $4.87 million from $3.04 million year-over-year, while general and administrative expenses increased to $5.30 million. The company expects steady expenses through 2022.
NeuroSense Therapeutics (NASDAQ: NRSN) has received approval from Italy's Medicines Agency (AIFA) to enroll patients in its Phase 2b clinical trial, PARADIGM, for ALS treatment with lead candidate PrimeC. This trial is also ongoing in Israel and has FDA clearance for recruitment in the U.S. The study will randomize 69 ALS patients to receive either PrimeC or placebo, assessing efficacy and safety over 6 months. PrimeC aims to mitigate ALS's motor neuron degeneration using a novel drug combination. This milestone expands patient access to potentially beneficial treatment options.